FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
24 January 2025
Foley Viewpoints
Incoming Environmental Protection Agency (EPA) Personnel and Impact on Enforcement
To nobody’s surprise, it is already evident that President Trump’s second term will mark a significant shift in environmental regulation and policy from the Biden Administration.
24 February 2025
Events
Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking in the Health Care Compliance Board & Compliance Committee Conference in the panel “Corporate Integrity Agreements: Independent Review of Organizations and the Office of the Inspector General.”
24 January 2025
Foley Viewpoints
Corporate Transparency Act Enforcement Remains Paused
On January 23, 2025, the U.S. Supreme Court issued a stay of the nationwide preliminary injunction issued by a federal district court in Texas in December 2024 in the Texas Top Cop Shop litigation.